Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 11—November 2004

Evaluating Human Papillomavirus Vaccination Programs

Al V. Taira*, Christopher P. Neukermans†, and Gillian D. Sanders†‡Comments to Author 
Author affiliations: *Stanford School of Medicine, Stanford, California, USA; †Stanford University, Stanford, California, USA; ‡Duke University, Durham, North Carolina, USA

Main Article

Table 2

Total discounted healthcare costs, total discounted life expectancy in years, and total quality-adjusted discounted lifetime expectancy in years are presented for prevaccination, and for female-only and male + female vaccination scenarios.

Outcome No vaccination HPV-16/18 vaccination
Female-onlya Female + maleb
Cost, $ 40,423 40,667 40,929
Incremental cost, $ 244 261
Life expectancy, y 28.7975 28.8112 28.8117
Incremental life expectancy, d 5.0 0.18
Quality-adjusted life expectancy, y 27.7422 27.7590 27.7596
Incremental quality-adjusted life expectancy, d 6.1 0.21
Incremental cost-effectiveness
$ per life-year 17,802 534,317
$ per quality-adjusted life-year 14,583 442,039
% reduction in lifetime cervical cancer cases 61.8 2.2

aIncremental to no vaccination strategy.
bIncremental to a female-only vaccination strategy.

Main Article

Page created: April 17, 2012
Page updated: April 17, 2012
Page reviewed: April 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.